American Society of Hirudotherapy

Evaluation of mechanical thrombectomy in acute ischemic stroke related to a distal arterial occlusion: A randomized controlled trial

Study protocol for a randomized controlled trial published in International journal of stroke : official journal of the International Stroke Society (2023)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Randomized controlled trialClinical LiteratureDrug DevelopmentClarençon F et al. · International journal of stroke : official journal of the International Stroke Society, 2024

Abstract

RATIONALE: Mechanical thrombectomy (MT) associated with the best medical treatment (BMT) has recently shown efficacy for the management of acute ischemic stroke (AIS) secondary to a large vessel occlusion. However, evidence is lacking regarding the benefit of MT for more distal occlusions. AIM: To evaluate the efficacy in terms of good clinical outcome at 3 months of MT associated with the BMT over the BMT alone in AIS related to a distal occlusion. METHODS: The DISCOUNT trial is a multicenter open-label randomized controlled trial involving French University hospitals. Adult patients (⩾18 years) with an AIS involving the anterior or posterior circulation secondary to a distal vessel occlusion within 6 h of symptom onset or within 24 h if no hyperintense signal on fluid attenuation inversion recovery acquisition will be randomized 1:1 to receive either MT associated with the BMT (experimental group) or BMT alone (control group). The number of patients to be included is 488. STUDY OUTCOMES: The primary outcome is the rate of good clinical outcome at 3 months defined as a modified Rankin scale (mRS) ⩽2 and evaluated by an independent assessor blinded to the intervention arm. Secondary outcomes include recanalization of the occluded vessel within 48 h, angiographic reperfusion in the experimental group, 3-month excellent clinical outcome (mRS ⩽ 1), all adverse events, and death. A cost utility analysis will estimate the incremental cost per quality-adjusted life year (QALY) gained. DISCUSSION: If positive, this study will open new insights in the management of AISs. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05030142 registered on 1 September 2021.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeRandomized Controlled TrialMulticenter StudyJournal Article
Indexed MeSH termsAdultHumansIschemic StrokeStrokeTreatment OutcomeThrombectomyArterial Occlusive DiseasesBrain Ischemia

Summary

DISCOUNT is a multicenter randomized controlled trial that will enroll 488 adults with acute ischemic stroke from distal vessel occlusion to compare mechanical thrombectomy plus best medical treatment against best medical treatment alone; the primary outcome is good clinical outcome at three months.

Context

This is the rationale and design paper for the DISCOUNT trial, a multicenter open-label randomized controlled trial in French hospitals planning to enroll 488 patients to test whether mechanical thrombectomy plus best medical treatment outperforms best medical treatment alone for acute ischemic stroke caused by a distal (rather than large) vessel occlusion, with good clinical outcome (modified Rankin scale <=2 at 3 months) as the primary endpoint. It illustrates that even for established thrombo-occlusive emergencies the evidence base is built endpoint by endpoint through rigorous RCTs, the same standard against which any hirudotherapy claim should be measured. Caveat: this abstract describes a protocol only, reporting no results or efficacy data; the trial was registered (NCT05030142) but outcomes were pending, and the study concerns device-based thrombectomy, not leech therapy or the secretome.

Citation

Reference (Vancouver style)

Clarençon F, Durand-Zaleski I, Premat K, Baptiste A, Chabert E, Ferrier A, et al. Evaluation of mechanical thrombectomy in acute ischemic stroke related to a distal arterial occlusion: A randomized controlled trial. Int J Stroke. 2024;19(3):367-372. doi:10.1177/17474930231205213. PMID: 37740419

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.